In a report issued on December 22, Jason Kolbert from Dawson James maintained a Hold rating on Brainstorm Cell Therapeutics (BCLI – Research Report). The company's shares closed last Tuesday at $4.01. According to TipRanks.com, Kolbert has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Sorrento Therapeutics, and Anavex Life Sciences. Brainstorm Cell Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.00. See today’s best-performing stocks on TipRanks >> Brainstorm Cell Therapeutics' market cap is currently $145.
https://www.tipranks.com/news/blurbs/brainstorm-cell-therapeutics-bcli-gets-a-hold-rating-from-dawson-james?utm_source=advfn.com&utm_medium=referral
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.